GlassScriptPhysician profile
Joseph C Wu
NPI 1659436186
$45,422.03
in general payments reported to CMS, 2019-2025
15 companies · $17.49 in 2025
The $17.49 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,823 · 2020: $4,671 · 2021: $5,000 · 2022: $9,804 · 2023: $4,163 · 2024: $13K · 2025: $17.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $17K · Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $16,902.50 |
| Food and Beverage | $222.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $12,000.00 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $8,691.18 | 2019-2022 | |
| Abbvie INC. | $8,480.48 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,000.00 | 2023 | |
| Genentech USA, INC. | $2,940.00 | 2024 | |
| Pfizer INC. | $2,845.17 | 2019-2020 | |
| Novo Nordisk INC | $1,997.50 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $1,625.56 | 2020-2022 | |
| Novo Nordisk As | $1,500.00 | 2020 | |
| Eli Lilly and Company | $1,400.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $678.64 | 2020 | |
| Medtronic Vascular, INC. | $121.68 | 2019 | |
| Abbott Laboratories | $105.50 | 2024 | Absolute Pro |
| Genentech, INC. | $18.83 | 2024 | |
| Cordis US Corp. | $17.49 | 2025 | Mynx Control Venous |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.